NDA 201367 · Eisai INC
Banzel
Rufinamide · Oral
OrphanLast checked: Nov 19, 2026Latest source record: May 30, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Mar 3, 2011
Approved uses
2
Original approval plus efficacy supplements
Registered trials
12
6 Phase 3, 0 recruiting
FAERS reports
2,630
1,882 serious, 154 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 15, 2022.
1 I NDICATIONS AND USAGE BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults. BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults ( 1 )
Mechanism: The precise mechanism(s) by which rufinamide exerts its antiepileptic effect is unknown. The results of in vitro studies suggest that the principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Rufinamide (≥ 1 μM) significantly slowed sodium channel recovery from inactivation after a prolonged prepulse in cultured cortical neurons, and limited sustained repetitive firing of sodium-dependent action potentials (EC 50 of 3.8 μM).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 12, 2015 Supplement 3 · Efficacy · priority review OrphanLabelLetter
- Mar 3, 2011 Original approval · Type 3 - New Dosage Form OrphanSummary ReviewPediatric Medical ReviewPediatric Clinical Pharmacology Review
1 products under this application
- BANZEL · RUFINAMIDE 40MG/ML · SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Rufinamide" as an intervention, any sponsor and status, largest first.
- Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial SeizuresPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00334958 · 356 participants · Start Feb 13, 2006 · Primary completion May 20, 2009
Drug: Placebo; Rufinamide · For: Epilepsy
Sites: Mobile, Alabama; Northport, Alabama; Phoenix, Arizona · 77 sites in all
- Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial SeizuresPivotal-lookingTerminated
Eisai Inc.Eisai
NCT00448539 · 286 participants · Start Mar 15, 2007 · Primary completion May 14, 2010
Drug: Rufinamide · For: Refractory Partial Onset Seizures
Sites: Mobile, Alabama; Little Rock, Arkansas; Bradenton, Florida · 27 sites in all
- Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)Pivotal-lookingCompleted
Biotie Therapies Inc.Industry
NCT00595231 · 239 participants · Start Mar 2008 · Primary completion Oct 2008
Drug: SYN111; Placebo · For: Generalized Anxiety Disorder
Sites: Atlanta, Georgia; Dayton, Ohio
- Ketogenic Diet in Infants With Epilepsy (KIWE)Pivotal-lookingStatus unknown
University College, LondonAcademic, hospital or other
NCT02205931 · 160 participants (planned) · Start Jan 2015 · Primary completion Jun 2018
Drug: Antiepileptic drug therapy · For: Epilepsy
Sites: Birmingham, United Kingdom; Bristol, United Kingdom; Cambridge, United Kingdom · 11 sites in all
- A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)Pivotal-lookingCompleted
Eisai LimitedEisai
NCT01146951 · 66 participants · Start Jun 2010 · Primary completion Aug 2011
Drug: Rufinamide (E2080); Placebo · For: Lennox-Gastaut Syndrome
Sites: Nagoya, Japan; Matsuyama, Japan; Fukuoka, Japan · 23 sites in all
Oslo University HospitalAcademic, hospital or other
NCT00552526 · 60 participants (planned) · Start Nov 2007 · Primary completion Jan 2011
Drug: Antiepileptic drug (AED) · For: Epilepsy; Mental Retardation
Sites: Oslo, Norway
- A Long Term Extension Study of E2080 in Lennox-Gastaut PatientsPivotal-lookingCompleted
Eisai Co., Ltd.Eisai
NCT01151540 · 54 participants · Start Nov 2010 · Primary completion Aug 2013
Drug: Rufinamide · For: Lennox-Gastaut Syndrome
Sites: Nagoya, Japan; Matsuyama, Japan; Fukuoka, Japan · 23 sites in all
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT02332174 · 40 participants · Start Mar 2014 · Primary completion Jun 2014
Drug: rufinamide · For: Seizures
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure670
- drug ineffective408
- off label use256
- somnolence186
- diarrhoea120
- condition aggravated116
- fatigue111
- vomiting108
- drug interaction106
- multiple-drug resistance102
- generalised tonic-clonic seizure95
- decreased appetite91
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 38 |
| 2010 | 27 |
| 2011 | 23 |
| 2012 | 49 |
| 2013 | 63 |
| 2014 | 93 |
| 2015 | 113 |
| 2016 | 130 |
| 2017 | 97 |
| 2018 | 136 |
| 2019 | 284 |
| 2020 | 237 |
| 2021 | 288 |
| 2022 | 246 |
| 2023 | 161 |
| 2024 | 268 |
| 2025 | 229 |
| 2026 | 145 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Banzel (Rufinamide)
2024 spending
$17.6M
Beneficiaries
480
3,673 claims
Per beneficiary
$36,620
$21.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $116,301,070 |
| 2021 | $79,885,763 |
| 2022 | $27,832,595 |
| 2023 | $21,938,164 |
| 2024 | $17,577,531 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T, Battino D, Bromley R, et al. · Epileptic Disord 2022 · Systematic Review
- Rufinamide add-on therapy for drug-resistant epilepsy.
Panebianco M, Prabhakar H, Marson AG · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Treatment of Lennox-Gastaut syndrome.
Hancock EC, Cross JH · Cochrane Database Syst Rev 2013 · Research Support, Non-U.S. Gov't, Systematic Review
- Anti-seizure medications for Lennox-Gastaut syndrome.
Brigo F, Jones K, Eltze C, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Rufinamide add-on therapy for refractory epilepsy.
Panebianco M, Prabhakar H, Marson AG · Cochrane Database Syst Rev 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
Sponsor: Eisai
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.